Partnering with Dianosic
Dianosic de-risks formulation, preclinical in vivo activities and ensures Clinical readiness. We integrate your API into our proprietary intranasal solid dosage form and also provide access to our internal programs.
Our platform is designed for pharmaceutical co-development
Unlike incremental improvements to existing delivery routes, our platform of long-acting solid dosage forms autonomously delivers the active pharmaceutical ingredient with no daily
patient involvement. The bioresorbable nature of our insert ensures excellent nasal retention without compromising patient quality of life.
This drug-enabling ‘insert and forget’ intranasal solution represents a compelling value proposition for pharmaceutical companies seeking disruptive modes of administration. Our approach offers a significant differentiation for selected molecules.
Our collaboration models: flexibility and optionality combined with speed
1. Classic co-development | Your small molecule, our platform
Integrate your API into our platform. Based on your expected Target Product Profile, we work jointly on customized formulations and preclinical in vivo validation — accelerating time-to-proof-of-concept with a de-risked, proprietary intranasal solid dosage form.
2. Leverage our current programs | Get access to our respiratory and brain diseases internal programs
Build co-development activities to support further advancement of our chronic allergic rhinitis, chronic rhinosinusitis and schizophrenia programs (e.g clinical trials).
3. Strategic alliance | Breaking barriers beyond small molecules
Dianosic is open to exploring collaborations for other
-
therapeutic modalities on a case-by-case basis.
Therapeutic areas open to partnering
- Respiratory — Chronic Allergic Rhinitis, Chronic Rhinosinusitis
- Neuropsychiatry — Schizophrenia, depression, PTSD…
- Neurodegenerative — Alzheimer’s disease, Parkinson’s disease, Lewy Body Dementia (LBD)…
- Neurology — Epilepsy
- Other potential indications
